The News
Rakovina Therapeutics Inc. has successfully closed a private placement of convertible debenture units, raising $1 million. This funding is aimed at advancing their innovative cancer therapies powered by AI-driven drug discovery.
Why It Matters
The company conducted a non-brokered private placement, allowing them to directly sell convertible debenture units to investors. This approach provides Rakovina with immediate capital while offering investors the potential for future equity conversion.
Key Evidence
The announcement confirms the closing of the Debenture Private Placement, which is expected to support the company's ongoing development efforts in cancer therapies.
Source
aktiencheck
DE source 路 Published 3d ago